BARBARA WEISER, M.D.; MICHAEL LANGE, M.D.; MARK A. FIALK, M.D.; CAROL SINGER, M.D.; TED H. SZATROWSKI, Ph.D.; DONALD ARMSTRONG, M.D.
We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitalizations to treat fever or infection (10 versus 12), number of documented infections (eight versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.
WEISER B, LANGE M, FIALK MA, et al. Prophylactic Trimethoprim-Sulfamethoxazole During Consolidation Chemotherapy for Acute Leukemia: A Controlled Trial. Ann Intern Med. 1981;95:436–438. doi: 10.7326/0003-4819-95-4-436
Download citation file:
Published: Ann Intern Med. 1981;95(4):436-438.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use